Citigroup’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$16.1M Sell
115,200
-44,800
-28% -$6.27M 0.01% 1196
2025
Q4
$19.6M Hold
160,000
0.01% 1120
2025
Q3
$17.8M Buy
160,000
+1,800
+1% +$205K 0.01% 1136
2025
Q2
$17.5M Sell
158,200
-24,000
-13% -$2.55M 0.01% 1038
2025
Q1
$20.4M Sell
182,200
-109,500
-38% -$11.3M 0.01% 961
2024
Q4
$26.9M Buy
291,700
+100,000
+52% +$9M 0.02% 798
2024
Q3
$16.1M Sell
191,700
-72,200
-27% -$5.51M 0.01% 1059
2024
Q2
$18.1M Buy
263,900
+107,400
+69% +$7.17M 0.01% 934
2024
Q1
$11.5M Sell
156,500
-218,000
-58% -$16.8M 0.01% 1174
2023
Q4
$30.3M Sell
374,500
-100,000
-21% -$7.78M 0.02% 662
2023
Q3
$35.6M Buy
474,500
+237,000
+100% +$18.2M 0.03% 550
2023
Q2
$18.3M Buy
237,500
+30,000
+14% +$2.39M 0.01% 864
2023
Q1
$17.2M Sell
207,500
-501,500
-71% -$41.5M 0.01% 891
2022
Q4
$60.9M Sell
709,000
-150,000
-17% -$11.9M 0.05% 348
2022
Q3
$53M Buy
859,000
+62,500
+8% +$3.94M 0.04% 357
2022
Q2
$49.2M Sell
796,500
-377,500
-32% -$23.4M 0.04% 391
2022
Q1
$69.8M Sell
1,174,000
-480,000
-29% -$30.7M 0.04% 374
2021
Q4
$120M Buy
1,654,000
+1,045,000
+172% +$72M 0.06% 270
2021
Q3
$42.5M Buy
609,000
+150,000
+33% +$10.5M 0.03% 608
2021
Q2
$31.6M Sell
459,000
-411,000
-47% -$27.4M 0.02% 752
2021
Q1
$56.2M Sell
870,000
-250,800
-22% -$16.2M 0.04% 454
2020
Q4
$65.3M Buy
1,120,800
+271,200
+32% +$16.4M 0.04% 423
2020
Q3
$53.7M Buy
849,600
+48,300
+6% +$3.35M 0.04% 421
2020
Q2
$61.7M Sell
801,300
-548,700
-41% -$42.1M 0.05% 342
2020
Q1
$101M Buy
1,350,000
+329,100
+32% +$22.7M 0.09% 185
2019
Q4
$66.3M Buy
1,020,900
+283,300
+38% +$18.4M 0.05% 377
2019
Q3
$46.7M Sell
737,600
-31,000
-4% -$2.03M 0.04% 488
2019
Q2
$51.9M Sell
768,600
-66,300
-8% -$4.36M 0.04% 427
2019
Q1
$54.3M Sell
834,900
-187,900
-18% -$12.5M 0.05% 370
2018
Q4
$64M Sell
1,022,800
-121,700
-11% -$8.51M 0.06% 302
2018
Q3
$88.4M Sell
1,144,500
-123,400
-10% -$9.32M 0.08% 219
2018
Q2
$89.8M Sell
1,267,900
-13,500
-1% -$953K 0.08% 193
2018
Q1
$96.6M Buy
1,281,400
+119,800
+10% +$9.52M 0.08% 208
2017
Q4
$83.2M Buy
1,161,600
+71,600
+7% +$5.44M 0.07% 261
2017
Q3
$88.3M Buy
1,090,000
+275,900
+34% +$21.1M 0.07% 227
2017
Q2
$57.6M Sell
814,100
-520,600
-39% -$34.6M 0.05% 296
2017
Q1
$90.7M Buy
1,334,700
+615,800
+86% +$43.3M 0.08% 204
2016
Q4
$51.5M Sell
718,900
-385,800
-35% -$28.7M 0.05% 378
2016
Q3
$87.4M Buy
1,104,700
+229,800
+26% +$18.7M 0.08% 218
2016
Q2
$73M Buy
874,900
+213,400
+32% +$18.9M 0.07% 246
2016
Q1
$60.8M Sell
661,500
-1,231,200
-65% -$111M 0.07% 262
2015
Q4
$192M Buy
1,892,700
+484,700
+34% +$50.4M 0.19% 83
2015
Q3
$138M Sell
1,408,000
-568,800
-29% -$63.2M 0.13% 116
2015
Q2
$231M Sell
1,976,800
-340,200
-15% -$37.2M 0.21% 59
2015
Q1
$227M Sell
2,317,000
-428,100
-16% -$43.5M 0.22% 61
2014
Q4
$259M Buy
2,745,100
+239,900
+10% +$24.8M 0.23% 56
2014
Q3
$267M Buy
2,505,200
+125,600
+5% +$12.3M 0.23% 48
2014
Q2
$197M Sell
2,379,600
-333,000
-12% -$25.9M 0.19% 73
2014
Q1
$192M Sell
2,712,600
-490,700
-15% -$38.5M 0.2% 71
2013
Q4
$241M Buy
3,203,300
+833,000
+35% +$58M 0.22% 65
2013
Q3
$149M Buy
2,370,300
+457,100
+24% +$27.3M 0.14% 113
2013
Q2
$98M Buy
+1,913,200
New +$99.7M 0.1% 155

Other funds holding GILD

Citigroup's GILD Position: Q1 2026 in Review

Citigroup increased its Gilead Sciences (GILD) stake by 30% in Q1 2026, buying an estimated $73.4M and bringing the position to 2,300,271 shares worth $321M. The position accounts for 0.14% of the portfolio, ranked #145.

Citigroup first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Citigroup held 2,300,271 shares of Gilead Sciences worth $321M as of Q1 2026.
  • Citigroup bought 524,041 Gilead Sciences shares in Q1 2026, an estimated $73.4M.
  • Gilead Sciences made up 0.14% of Citigroup's portfolio in Q1 2026, its #145 holding.
  • Citigroup first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.